1-11 of 11
Shreya Vemuri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma

Ariela Noy, Win Su Thet, Shreya Vemuri, Venkatraman Seshan, Connie Lee Batlevi, Zachary D. Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Thomas M. Habermann, Paul A. Hamlin, Erel Joffe, Jennifer Kimberly Lue, Matthew Matasar, Maria Lia Palomba, Andrew D. Zelenetz, Gilles Salles
Journal: Blood
Blood (2024) 144 (Supplement 1): 6352.
https://doi.org/10.1182/blood-2024-211730
Published: 2024
Journal Articles

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Raphael Steiner, Liana Nikolaenko, Swetha Kambhampati, Niloufer Khan, Ranjit Nair, Jeremy S. Abramson, Steven Horwitz, Matthew Matasar, Colette Owens, Ildefonso Ismael Rodriguez Rivera, David J. Straus, Timothy S Pardee, Sanjeev Luther, Win Su Thet, Shreya Vemuri, Ariela Noy
Journal: Blood
Blood (2024) 144 (Supplement 1): 1729.
https://doi.org/10.1182/blood-2024-202459
Published: 2024
Journal Articles

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Clinical Trials & Observations
Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M. Stone, Alan Saven, Jessica K. Altman, Michael R. Grever, Kanti R. Rai, Madhulika Shukla, Shreya Vemuri, Skye Montoya, Justin Taylor, Omar Abdel-Wahab, Martin S. Tallman, Jae H. Park
Journal: Blood
Blood (2022) 140 (25): 2663–2671.
https://doi.org/10.1182/blood.2022016183
Published: 2022
Journal Articles

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Robert Stuver, Laure Michaud, Carla Casulo, Ranjana H. Advani, Elizabeth L. Budde, Paul M. Barr, Connie Lee Batlevi, Philip C Caron, Louis S. Constine, Savita Dandapani, Pamela Drullinsky, Jonathan W. Friedberg, Clare Grieve, Audrey Hamilton, Paul A. Hamlin, Richard Hoppe, Steven M. Horwitz, Niloufer Khan, Matthew J. Matasar, Ariela Noy, M.Lia Palomba, Heiko Schoder, David J. Straus, Shreya Vemuri, Joachim Yahalom, Joanna C. Yang, Anas Younes, Andrew D. Zelenetz, Craig H. Moskowitz, Anita Kumar, Alison J. Moskowitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 1756–1758.
https://doi.org/10.1182/blood-2022-156382
Published: 2022
Journal Articles

A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Anita Kumar, Jason R. Westin, Stephen J. Schuster, Grzegorz S. Nowakowski, Izidore S. Lossos, Devin Copley, Clare Grieve, Allison P. Jacob, Ashlee Joseph, Leana Laraque, Gita Masand, Chelsea D Mullins, Ellen Napier, Tania Rodriguez, Venkatraman Seshan, Shreya Vemuri, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 138 (Supplement 1): 52.
https://doi.org/10.1182/blood-2021-150572
Published: 2021
Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H Park, Eric S. Winer, Scott F. Huntington, Gottfried von Keudell, Shreya Vemuri, Madhulika Shukla, Julie C Kinoshita, Victoria Falco, Steven D. Gore, Richard M. Stone, Omar Abdel-Wahab, Martin S. Tallman
Journal: Blood
Blood (2021) 138 (Supplement 1): 43.
https://doi.org/10.1182/blood-2021-151074
Published: 2021
Journal Articles

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Anita Kumar, MD, Jason Westin, MD, Stephen J Schuster, MD, Grzegorz S. Nowakowski, MD, Izidore S. Lossos, MD, Connie Lee Batlevi, MDPhD, Philip Caron, MD PhD, Pamela Drullinsky, MD, John Gerecitano, MD PhD, Audrey Hamilton, MD, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Allison P. Jacob, Erel Joffe, MD MSc, Ashlee Joseph, Gottfried R. von Keudell, MD PhD, Leana Laraque, BA, Oscar B Lahoud, MD, Matthew J Matasar, MD, Craig H. Moskowitz, MD, Chelsea D Mullins, BS, Ariela Noy, MD, Colette Owens, MD, Maria Lia Palomba, Carol S. Portlock, MD, Ildefonso Rodriguez-Rivera, MD, Gilles Salles, MDPhD, Venkatraman Seshan, PhD, David J. Straus, MD, Shreya Vemuri, Anas Younes, Andrew D Zelenetz, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-138889
Published: 2020
Journal Articles

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Anita Kumar, MD, Carla Casulo, Ranjana H Advani, MD, Lihua E Budde, MD PhD, Paul M. Barr, MD, Connie Lee Batlevi, MD PhD, Philip Caron, MD PhD, Louis S. Constine, MD, Savita Dandapani, MD PhD, Esther Drill, PhD, Pamela Drullinsky, MD, Jonathan W. Friedberg, MD, Clare Grieve, BA, Audrey Hamilton, MD, Paul A. Hamlin, MD, Richard T Hoppe, MD, Steven M. Horwitz, MD, Matthew J Matasar, MD, Susan Jennifer McCall, NP, Alison J. Moskowitz, MD, Ariela Noy, MD, Maria Lia Palomba, MD, Heiko Schoder, MD, David J. Straus, MD, Shreya Vemuri, Joanna C Yang, MD MPH, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz
Journal: Blood
Blood (2019) 134 (Supplement_1): 2834.
https://doi.org/10.1182/blood-2019-123150
Published: 2019
Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3998.
https://doi.org/10.1182/blood-2019-124478
Published: 2019
Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 392.
https://doi.org/10.1182/blood-2018-99-119949
Published: 2018
Journal Articles

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Mark Blaine Geyer, MD, Ellen K. Ritchie, MD, Arati V. Rao, MD, M. Isabella Cazacu, Shreya Vemuri, Martin S. Tallman, MD, Dan Douer, MD, Jae H. Park, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4013.
https://doi.org/10.1182/blood-2018-99-115486
Published: 2018